Примаксетин

Quick links to important sections

Примаксетин

Selected form

Method of action: Urologicals

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Примаксетин

Quick Facts

Property Description
Active ingredient Dapoxetine
Form Film-coated tablets
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
General purpose Enhancing voluntary control over the timing of ejaculation
Origin Synthetic chemical compound

Identity, Classification, and Composition of Примаксетин

Примаксетин is a specialized pharmaceutical preparation intended for oral administration, formulated as a single-ingredient product in the form of a film-coated tablet. The active component is Dapoxetine, which is a synthetic chemical compound and a naphthalene derivative. Dapoxetine's distinct pharmacological classification places it within the group of Selective Serotonin Reuptake Inhibitors (SSRIs), but it is uniquely engineered for rapid action. The medication is officially recognized for its urological application, which highlights its focused development as a treatment agent.

The Unique Pharmacological Profile of Dapoxetine

Dapoxetine is fundamentally characterized as a short-acting SSRI, a feature that critically distinguishes it from related SSRI compounds used for sustained chronic treatment. This unique profile is characterized by the substance’s rapid absorption and exceptionally swift metabolic clearance from the body. This rapid pharmacokinetic property provides the necessary foundation for its specific intended use, ensuring that the pharmacological influence is transient. The core mechanism involves a temporary influence on the serotonin transporter, effectively modulating the neurotransmitter serotonin within the central nervous system circuitry that regulates the ejaculatory reflex.

General Purpose and Therapeutic Application

The primary function of this medication is to serve as an on-demand treatment for adult men seeking to enhance voluntary control over the timing of ejaculation. The specific pharmacological effect of modulating the ejaculatory reflex is associated with a measurable prolongation of the Intravaginal Ejaculatory Latency Time (IELT). This targeted action establishes its specialized purpose, utilizing its quick-in, quick-out profile to achieve a precise therapeutic goal without requiring the systemic exposure associated with continuous, daily pharmacological therapy.

Regulatory References

  1. NIH Study on Dapoxetine Pharmacokinetics

What side effects are possible with Примаксетин?

Possible side effects and safety information

The safety profile of Примаксетин (Dapoxetine) is based on official government regulatory classifications, which categorize adverse reactions by frequency and physiological system. The most frequent effects are generally reported in the nervous and gastrointestinal systems.

Frequency-Classified Adverse Reactions

The regulatory label identifies effects occurring across several frequency tiers:

  • Very Common (affecting 1 in 10 or more men): Nausea, Headache, and Dizziness.
  • Common (affecting less than 1 in 10 men): Insomnia, Anxiety, Diarrhea, Somnolence (drowsiness), Fatigue, Dry mouth, and Erectile dysfunction.
  • Uncommon (affecting less than 1 in 100 men): Reactions involving the cardiovascular and neurological systems, such as Syncope (loss of consciousness), Orthostatic hypotension, and Palpitations.

Serious Adverse Reactions and Safety Constraints

Official documents specifically list Syncope as a serious adverse reaction, noting it is often vasovagal in origin. This event, along with other adverse effects, is documented as being dose-dependent and most likely to occur within the first three hours after administration.

The medication's use is strictly limited by certain contraindications outlined in regulatory labels. It is not to be used in individuals with moderate or severe hepatic impairment or those with certain significant pathological cardiac conditions. Furthermore, it is restricted for patients with a history of syncope or mania/severe depression. Concomitant use with other serotonergic agents (such as MAOIs or SSRIs) is prohibited due to the risk of Serotonin Syndrome.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define the overdose profile of Dapoxetine by documenting the potential for specific manifestations and outlining mandatory emergency actions. Suspected overdose is officially reported to present with primary manifestations of Nausea and Vomiting. Clinical risks documented in the label are centered on the Central Nervous System and Cardiovascular System.

Severe symptoms, such as seizures or fainting (syncope), are considered critical events and mandate immediate medical attention. Syncope is associated with severe cardiovascular effects like Bradycardia or Sinus Arrest, requiring professional clinical management. Due to its pharmacological classification, the drug also carries the official class risk of Serotonin Toxicity, a serious potential complication.

If an overdose is suspected, official guidance requires the user to Contact a Doctor or Pharmacist Immediately. The management of overdose must be strictly limited to symptomatic and supportive treatment, as regulatory agencies affirm that no specific antidote is known for Dapoxetine. It is also noted that the incidence and severity of adverse effects are higher with the 60 mg dose, which establishes a clear dose-response relationship for adverse risk.

Therapeutic Uses of Примаксетин

The medication may be part of symptomatic management applied across domains where additional symptomatic support is needed. It is utilized in contexts characterized by periods of heightened symptoms, specifically for easing symptoms in three main categories: persistent low mood, chronic worry and physical tension, and symptoms related to chronic neuropathic pain.

Relief from Persistent Low Mood and Depression Symptoms

This medication is used in situations involving certain distressing symptoms related to persistent low mood and a significant lack of enjoyment. It is applied in addressing symptom clusters that may become intense or disruptive, such as persistent sadness and a loss of pleasure. It contributes to easing the overall symptom load and may assist with maintaining functional stability.

Management of Chronic Worry and Generalized Anxiety

It is relevant in contexts marked by increased discomfort or tension, applied in conditions where symptoms may intensify temporarily. It is commonly used to help manage chronic, excessive worry and symptoms related to physical discomfort (like muscle tension), offering symptomatic relief that helps patients cope more steadily.


Quick Fact: Symptomatic Support for Chronic Discomfort The medication is applied when symptoms create noticeable functional strain, such as burning or shooting nerve sensations, which contributes to easing the overall symptom load and supports patients during episodes of heightened discomfort.

Regulatory References

  1. European Medicines Agency therapeutic overview of Cymbalta

Eligibility and Restrictions for Use

Who can and cannot use Примаксетин

Примаксетин (Dapoxetine) is officially labeled for use only in adult men aged 18 to 64 years who meet the formal diagnostic criteria for Premature Ejaculation. Regulatory guidelines strictly define populations for whom the medicine is restricted or absolutely excluded.

The medicine is absolutely contraindicated for patients with a history of syncope (fainting), mania or severe depression, or specific significant pathological cardiac conditions, such as heart failure (NYHA class II-IV) or certain conduction abnormalities.

Eligibility Group Regulatory Status Restriction Context
Women Contraindicated No indicated use
Under 18 / Over 65 Not Recommended Safety and efficacy not established

Eligibility is also dependent on internal physiological status and concurrent medication use. The medicine is contraindicated in patients with moderate and severe hepatic impairment (liver disease) and is not recommended for those with severe renal impairment (kidney disease). Additionally, it must not be used concurrently with Monoamine Oxidase Inhibitors (MAOIs) or potent CYP3A4 inhibitors.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Примаксетин (Dapoxetine) has officially documented interaction patterns based on its pharmacokinetic profile and mechanism as a short-acting Selective Serotonin Reuptake Inhibitor (SSRI). Regulatory sources classify these interactions into two primary risk areas: those affecting plasma exposure and those causing additive pharmacodynamic effects.

Formally Documented Contraindications

Co-administration is contraindicated with several classes of medicinal products:

  • Monoamine Oxidase Inhibitors (MAOIs): Prohibited due to the risk of severe Serotonin Syndrome.
  • Potent CYP3A4 Inhibitors: Prohibited combinations (e.g., Ketoconazole, Ritonavir) due to the substantial increase in Dapoxetine plasma concentrations.
  • Thioridazine and other Serotonergic products (e.g., SSRIs, Tramadol) are also contraindicated due to the high risk of systemic toxicity or Serotonin Syndrome.

Exposure and Timing Constraints

Interactions involving the CYP3A4 and CYP2D6 enzymes may increase drug exposure, which warrants a dose restriction to 30 mg when co-administered with Moderate CYP3A4 Inhibitors. Mandatory timing rules require a 14-day washout period when initiating Dapoxetine after stopping an MAOI or Thioridazine, and a 7-day separation before starting an MAOI after stopping Dapoxetine. Furthermore, use with alcohol is advised against due to documented additive Central Nervous System (CNS) effects that increase the risk of syncope and dizziness.

Mechanism of Action

Примаксетин (Dapoxetine) functions as a selective serotonin reuptake inhibitor (SSRI). Its primary molecular target is the serotonin transporter (SERT), a monoamine transporter protein located on the presynaptic neuronal membrane. The drug acts as an inhibitor of SERT, binding to the transporter and preventing the reuptake of the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) from the synaptic cleft into the presynaptic neuron.

The immediate intracellular consequence is an elevated concentration of 5-HT within the synaptic cleft. This increased synaptic 5-HT concentration results in a greater duration and magnitude of activation of postsynaptic 5-HT receptors, particularly the 5-HT1A and 5-HT2C subtypes, which are concentrated in the central nervous system, including supraspinal and spinal ejaculatory centers. Elevated 5-HT signaling, mediated by specific receptor activation, modulates neural circuits involved in the ejaculatory reflex arc. This system-level physiological consequence is a modification of the afferent and efferent neurological control, resulting in a change in the timing of the somatic and sympathetic nervous system components of the ejaculatory process.

Dosage and Administration Information

The standard protocols for the administration of Примаксетин (Dapoxetine) describe its use as an on-demand oral medication. The established dosage for this film-coated tablet begins at 30 mg, which may be adjusted to a maximum dose of 60 mg.

The medicine is not intended for continuous, daily use; instead, the core principle of its use is timing, with the dose administered one to three hours prior to anticipated sexual activity. This on-demand schedule involves a constraint on frequency: the drug is not to be taken more than once within a 24-hour period, regardless of the strength consumed.

Regarding the conditions of ingestion, the tablets can be taken either with or without food. It is recommended as part of the administration process that the dose be swallowed whole with a full glass of water.

Administration also includes constraints related to specific patient populations. Use of the medicine has not been established in men aged 65 years and over, and use is not recommended in this demographic. Furthermore, the drug is contra-indicated for men diagnosed with moderate to severe hepatic impairment, serving as a critical constraint on its use. These details formalize the context and limits under which the medicine is administered.

Recent Clinical Evidence

Research evidence / Overview of studies for Примаксетин

Evidence for use in Premature Ejaculation

The evidence base for Примаксетин was studied for its use in managing Premature Ejaculation (PE), a condition studied in research contexts. The evidence base includes numerous large-scale, short-term, placebo-controlled Randomized Controlled Trials (RCTs). These study designs were utilized to observe adult men diagnosed with PE, regardless of whether their symptoms were lifelong or had developed later (acquired).

The research primarily examined two main outcomes related to physical discomfort and function. Studies monitored changes in the Intravaginal Ejaculatory Latency Time (IELT), which is the time measured from penetration until ejaculation. The second focus was on patient-reported outcomes describing perceived discomfort. These outcomes described episodic or acute changes and included measures such as how subjects reported their control over ejaculation and their satisfaction with sexual activity. Studies report how symptoms evolved in the observed populations over defined time intervals.

Findings from the Randomized Controlled Trials (RCTs) describe patterns observed in the studies over the short follow-up periods. Research also describes that the studies focusing on episodes where symptoms become more noticeable reported measured changes in IELT. Furthermore, findings contribute to understanding how patients reported their experience through measures like the Clinical Global Impression (CGI) of change.

Evidence in Specific Patient Groups

The primary research was evaluated in a broad group of adult men who met the clinical criteria for PE. Beyond the general PE population, studies also explored specific subgroups. This was studied for those with different types of PE, and for individuals who was observed in a research context involving fluctuating or unstable symptoms who were also taking other medication for Erectile Dysfunction (ED).

Duration of Studies and Long-Term Follow-up

The major clinical research was studied for its application over short-term and intermediate-term durations, typically lasting 12 to 24 weeks. The follow-up durations were limited by the design of the pivotal trials. Data show patterns related to outcomes measured during this specific study period.

The available data provides limited characterization of outcomes for treatment durations exceeding 24 weeks, meaning long-term effects are not fully established. While some studies monitored outcomes over slightly longer intervals, the evidence available to assess continued or sustained use beyond the primary 24-week study period is limited.

Evidence Gaps and Areas of Research Uncertainty

The research to date provides context but not individual predictions. Certain aspects of the medicine’s profile and use remain uncertain because they have not been fully characterized in controlled studies. Data for certain groups remain insufficient, particularly for men who were not in long-term, stable relationships, as these populations were generally excluded from the central clinical trials.

The evidence highlights what is known—and what is still uncertain. The body of evidence includes multiple large-scale, well-controlled RCTs for short-term outcomes. However, results apply only to the populations studied, and the limited information for long-term outcomes remains an area of research uncertainty.

Frequently Asked Questions (FAQ)

Common questions about Примаксетин (FAQ)


Q: Is Primaxetine considered a drug that can cause dependence or addiction?

Official documents classify Primaxetine as a short-acting selective serotonin reuptake inhibitor (SSRI). Clinical trials have not reported symptoms of dependence or drug-seeking behavior associated with its use. However, due to its classification, caution is advised when assessing its potential for abuse.


Q: What are the most common adverse reactions reported in studies of Primaxetine?

The most frequent adverse reactions reported in clinical trials are nausea, headache, and dizziness. Official documents classify these as 'very common' effects, reflecting the classification of 'very common' (affecting more than 1 in 10 men in studies).


Q: How long does it usually take to feel the effect of Primaxetine?

Official use guidelines indicate the medicine is taken one to three hours prior to anticipated sexual activity. This timing is based on pharmacokinetic studies showing that peak concentrations in the blood are generally reached within one to two hours after taking the dose.


Q: Is it true that Primaxetine is a 'new' or 'improved' drug compared to others?

Primaxetine is officially characterized as a short-acting SSRI. This unique classification is based on its profile of rapid absorption and swift elimination from the body. This characteristic makes it suitable for on-demand use, distinguishing it from other SSRI compounds used for continuous, daily treatment.


Q: Can I take Primaxetine if I have liver problems?

The medication is strictly contraindicated for men diagnosed with moderate or severe hepatic impairment (liver disease). Use of the medicine is restricted due to the way it is metabolized in the liver.


Q: What should I do if I miss a dose of Primaxetine?

Since the drug is for situational use only, taken 1–3 hours before activity, it is not intended for continuous daily use. Regulatory information states that the medicine should not be taken more than once within a 24-hour period.


Q: What foods or drinks can poorly interact with Primaxetine?

Official warnings indicate that using Primaxetine in combination with alcohol is advised against. This is because the combination can increase the risk of neurocognitive adverse events like syncope (fainting) and dizziness. The tablets can generally be taken with or without food.


Q: Can Primaxetine be used to treat anxiety or only Premature Ejaculation?

Primaxetine is officially indicated only for the treatment of Premature Ejaculation (PE) in adult men. Its safety and efficacy have not been established for the treatment of psychiatric disorders, including clinical depression or anxiety.


Q: Have there been reports of 'withdrawal syndrome' after stopping Primaxetine?

Due to its rapid action and on-demand use, official data has not reported the classic withdrawal symptoms often seen with the abrupt cessation of other SSRI medications used long-term. However, as with all SSRIs, regulatory information indicates that abrupt cessation is generally not advised.


Q: Are special tests required before starting Primaxetine?

Before starting treatment, a careful medical examination is recommended. This assessment may involve a history check for fainting events and an orthostatic test, which measures blood pressure and pulse rate when changing position from lying down to standing.


Q: Can physical exercise or diet affect the efficacy of Primaxetine?

Official product information notes that the impact of food on the drug's absorption is not considered clinically significant. Official documents do not provide specific guidance on how general physical exercise or long-term diet may affect the medication's efficacy.


Q: Is Primaxetine a prescription drug or can it be bought over the counter?

Primaxetine is legally classified as a prescription-only medicine. It can only be obtained through a valid prescription from a licensed healthcare provider.


Q: What serious but rare side effects are associated with Primaxetine?

One serious adverse reaction reported in studies is syncope (loss of consciousness), which is classified as uncommon. Official documents also note rare events, such as dizziness that occurs specifically following physical exertion.


Q: Is there data on how Primaxetine affects body weight?

The official documents that classify adverse reactions by their frequency do not include data on changes in body weight (either gain or loss) associated with the use of this medicine.


Q: How long is it usually recommended to continue Primaxetine therapy?

Clinical trials supporting the drug's approval were limited to a duration of 24 weeks. Official recommendations state that after the first four weeks or first six doses of use, the risks and benefits of continuing the treatment are subject to physician assessment.


Q: What is known about the use of Primaxetine during pregnancy or breastfeeding?

Primaxetine is not indicated for use in women and is contraindicated during both pregnancy and the period of lactation (breastfeeding).


Q: Why do some people say that Primaxetine 'doesn't work' for them?

Official clinical data indicates that the response to the drug can be individual, and not all men achieve the desired results. Insufficient effectiveness may be due to the fact that a person's reaction depends on individual factors, including how quickly their body metabolizes the medicine.


Q: Is it true that this drug can cause sleep problems?

Yes, official documents classify insomnia (difficulty sleeping) as a common adverse event, affecting less than 1 in 10 men. Other reported effects in the same category include anxiety and unusual dreams.


Q: Can Primaxetine be taken if I have diabetes or heart problems?

The medicine is strictly contraindicated for patients with certain significant pathological cardiac conditions, such as severe heart failure. While there is no direct contraindication for patients with diabetes in official documents, precautions are generally required when taking the medicine.


Q: What are the general expectations from the first month of taking Primaxetine?

Clinical trial data showed that effects related to the delay of ejaculation can be observed over the short term. Physician evaluation is required to determine the necessity of continuing the therapy after the first four weeks or first six doses.


Q: Is it necessary to take Primaxetine at the same time every day?

No. Primaxetine is an on-demand medication, designed for situational use, not for a daily schedule. It is taken 1 to 3 hours before anticipated activity, and official guidelines state it should not be taken more than once within a 24-hour period.


Q: Can Primaxetine affect sexual function?

Yes. Adverse events related to sexual function reported in clinical studies include erectile dysfunction (common), as well as decreased libido and anorgasmia (uncommon).


Q: Does Primaxetine affect the ability to concentrate or work?

Official warnings state that Primaxetine has a minor or moderate influence on the ability to drive and operate machinery. Studies reported dizziness, disturbance in attention, and somnolence (drowsiness) among its side effects.


Q: Why might Primaxetine be preferred for some patients?

The potential preference for this drug is often related to its rapid pharmacokinetic profile. Its quick absorption and elimination were specifically developed for on-demand use, which avoids the prolonged systemic exposure that is associated with continuously taken SSRIs.


Q: Is Primaxetine considered safe for long-term use?

Official documents note that the pivotal clinical trials used to approve the drug were limited to a maximum duration of 24 weeks. Consequently, the data available to assess the safety and efficacy of use exceeding that period are considered limited or insufficient.


Q: How is Primaxetine metabolized (broken down) in the body?

The medicine is rapidly absorbed and undergoes extensive metabolism (breakdown) primarily in the liver. This process involves multiple enzymes, most notably CYP2D6 and CYP3A4, which result in the formation of active metabolites.


Q: Can the side effects of Primaxetine go away over time?

Adverse reactions such as nausea and dizziness are most frequently observed within the first three hours after a dose and after the initial dose. Official documents do not provide a general assessment of whether these effects typically disappear with continued use over time.


Q: How does Primaxetine affect the nervous system in general?

Primaxetine is an SSRI that works by temporarily blocking the reuptake of the neurotransmitter serotonin. This action increases the concentration of serotonin in the space between nerve cells, influencing the neural circuits involved in the ejaculatory reflex.


Q: Are there genetic factors that affect the response to Primaxetine?

Yes, official documents mention that caution is necessary when increasing the dose to 60 mg in patients who are known to be 'poor metabolizers' of the CYP2D6 enzyme. This characteristic, which is genetically determined, affects how the body breaks down the drug.


Q: How do I know if a question about Primaxetine is a normal reaction or a cause for concern?

Official documents specify that if certain symptoms, such as the initial signs of fainting (like nausea, light-headedness, or feeling weak), appear, official documents indicate that if symptoms appear, lying down or sitting down immediately may be necessary. Patients are warned to avoid situations where they might be injured if syncope were to occur.


Q: Does Primaxetine affect blood pressure?

Yes. The medicine can cause orthostatic hypotension (a sudden drop in blood pressure when standing up), which is classified as an uncommon adverse event. This effect is a documented cause of dizziness.


Q: What should I do if new or worsening symptoms appear while taking Primaxetine?

Official warnings state that consultation with a physician is necessary if new or worsening psychiatric symptoms appear. This includes changes such as the emergence of suicidal thoughts or an increase in agitation or manic behavior.


Q: Why is an adjusted dose ('titratable dose') often mentioned in the Primaxetine instructions?

Official instructions define that the starting dose of 30 mg may be adjusted upward to the maximum recommended dose of 60 mg. This adjustment must be based on a physician’s assessment of the patient's individual response to the initial dose and its safety profile.


Q: How is Primaxetine gradually withdrawn?

Given its short-acting, on-demand profile, official documents do not provide a standard tapering schedule like those used for daily SSRIs. However, the decision to discontinue or stop using the drug is subject to a medical consultation with a physician.


Q: Are there official restrictions on driving or operating machinery while taking Primaxetine?

Official warnings advise avoiding driving or operating hazardous machinery if symptoms occur, such as dizziness, disturbance in attention, somnolence (drowsiness), or syncope (fainting). These effects have been reported in studies.


Q: What do official documents say about Primaxetine overdose?

In human studies involving very high doses, adverse events such as sedation and vomiting were observed. Official guidance states that in case of an acute overdose, immediate supportive care and monitoring of the patient’s vital signs may be required.

How should Примаксетин be stored and disposed of?

The storage and disposal of Primaxetine (dapoxetine) must adhere strictly to the regulatory requirements defined in the official labeling to ensure product integrity and environmental protection.

Scope Item Official Regulatory Statement
Storage Temperature The product does not require any special temperature storage conditions; store at room temperature.
Protection Requirements Tablets must be stored in the original blister packaging to protect them from moisture and light.
Child-Protection Must be kept out of the sight and reach of children.
Disposal Instructions Unused or expired medicine must not be disposed of via wastewater or household waste; dispose of according to local regulatory requirements (e.g., return to a pharmacist).

Official storage and disposal statements: Regulatory documents specify that the tablets are stable at ambient room temperature and must remain in the original packaging for light and moisture protection. The official profile strictly mandates disposal as pharmaceutical waste, prohibiting flushing or discarding the medicine into household trash to prevent environmental contamination, and requires the medicine to be stored securely away from children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Примаксетин found in:

A-Z Index: